The Indenos were created specifically to address the shortcomings of conventional Top-1 Inhibitors. The NCI has invested significantly in all pre-clinical investigations and all 5 Phase 1 clinical trials for these compounds. Gibson Oncology, which owns the rights to the Indenos, now is planning Phase 2 trials for LMP400, LMP744, and LMP776.